Stay updated on Pembrolizumab and Lenvatinib in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page
- Check4 days agoChange DetectedAdded Padova, Italy, 35128 as a study location and removed Padua, Italy, 35128.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe Italian trial site entry was updated from Napoli, Italy, 80131 to Naples, Italy, 80131.SummaryDifference0.0%

- Check26 days agoChange DetectedAdded revision tag v3.5.0 and removed revision tag v3.4.3.SummaryDifference0.0%

- Check33 days agoChange DetectedRevision metadata updated from v3.4.2 to v3.4.3. No user-facing content or functionality changes.SummaryDifference0.0%

- Check61 days agoChange DetectedAdded Plain Language Summary and data-sharing links (Trialstransparency PDF, externaldatasharing-msd). Removed older EngageZone data-sharing documents and updated revision to v3.4.2.SummaryDifference0.2%

- Check68 days agoChange DetectedAdded Revision: v3.4.1 and removed Revision: v3.4.0; this appears to be revision metadata only. No study content such as eligibility criteria, locations, or outcomes has changed.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab and Lenvatinib in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Lenvatinib in Melanoma Clinical Trial page.